Background: Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defective production of reactive oxygen species in phagocytic cells that results in lifethreatening infections and severe inflammatory manifestations. The treatment of inflammatory manifestations remains challenging because it can be associated with an increased risk of infections. Previous studies have shown that phagocytes from patients with CGD display a defect in autophagy and a reactive oxygen species-independent activation of the inflammasome. Objective: Because the intersections between autophagy and the inflammasome have been observed in patients with various diseases and microbial infections, we investigated the possible benefit of restoring the autophagy defect through rapamycin, a potent autophagy inducer, in the setting of CGD. Methods: We studied 15 patients given a diagnosis of CGD and followed in our institution. All patients were free of any active infection at the time of the study. Results: We show that patients with CGD present a consistent inflammatory phenotype defined by (1) increased nonclassical and intermediate monocytes, (2) a proinflammatory state of mononuclear phagocytes with increased IL-1b and TNF-a content, (3) a T H 17 bias of CD4 1 T cells, (4) and an increase in IL-17A-secreting neutrophil numbers. We document the reversion
Chronic granulomatous disease (CGD) is a primary immunodeficiency of innate immunity caused by defects in phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits. Loss-of-function mutations in the NADPH oxidase components (ie, gp91phox, p22phox, p67phox, or p47phox) abrogate oxidase activity and compromise host immunity against certain bacteria and fungi. 1 Because a patient's life expectancy increases thanks to progress in diagnosis and management, the burden of inflammatory manifestations occurring independently of infectious agents has become more evident. Patients with CGD have granulomatous disorders, notably colitis, as a consequence of dysregulated inflammatory response. 2 The treatment of such manifestations remains challenging because it can be associated with an increased risk of infections. 3 Previous studies have shown that NADPH complex-deficient phagocytes display a defect in autophagy and reactive oxygen species-independent activation of the inflammasome. 4, 5 Because IL-1b blockade decreases the activation of inflammasome and restores autophagy in mice with CGD in vivo and in human cells in vitro, clinicians have been tempted to treat patients with CGD with the IL-1b receptor antagonist anakinra, with mixed results. 6, 7 Rapamycin is a macrolide naturally produced by the bacterium Streptomyces hygroscopicus, which was initially developed as an antifungal agent. 8 However, rapamycin, a potent mammalian target of rapamycin (mTOR) inhibitor, has mainly been used in clinical care for its immunosuppressive properties. 9 Through mammalian target of rapamycin complex 1 (mTORC1) inhibition, rapamycin has also been shown to act as an autophagy inducer. 10 Because intersections between autophagy and the inflammasome have been observed in patients with various diseases and microbial infections, we investigated the possible benefit of restoring the autophagy defect through rapamycin in the setting of CGD. 11 For this purpose, we investigated the biological inflammatory status of a French cohort of patients with CGD and performed an in vitro study of the effect of rapamycin treatment on immune cells from patients with CGD.
METHODS Patients
We studied 15 patients given a diagnosis of CGD followed in our institution. Characteristics of the patients are detailed in Table I . Informed consent for participation in the study was obtained from the patient's parents or from the patient in accordance with French regulatory requirements, the approval of the Institutional Review Board of the Necker-Enfants Malades Hospital, and the Declaration of Helsinki. Each patient's median age was 8 years (range, 1-22 years). No patients presented with active bacterial or fungal infection at the time of the study. Eight patients presented with inflammatory manifestations (colitis, n 5 7; granulomatous cystitis, n 5 1). The contribution of each patient with CGD to the biological study is detailed in Table E1 in this article's Online Repository at www.jacionline.org.
Cohort of healthy control subjects
The median age of the healthy control subjects (HCs) was 24 years (range, 2-56 years). The control cohort comprised 5 children (2, 4, 7, 10, and 14 years old). We did not observe any significant correlation between the age of the HCs and the different biological parameters evaluated. The contribution of each HC to the biological study is detailed in Table E2 in this article's Online Repository at www.jacionline.org.
Monocyte, CD4
1 T-cell, neutrophil, and monocytederived macrophage assays
All assays, including cell isolation, flow cytometric analysis, cell stimulation analysis, cytokine secretion assay, macrophage differentiation, caspase-1 activation assay, and immunofluorescence detection of microtubule-associated protein 1A/1B-light chain 3 (LC3), were performed according to standard protocols. Detailed methods are provided in the Methods section in this article's Online Repository at www.jacionline.org.
Statistical analysis
Statistical analysis was performed with GraphPad Prism software (version 6.0; GraphPad Software, La Jolla, Calif). The Mann-Whitney U test was used for comparison of unpaired values, whereas the Wilcoxon paired t test was used for comparison of paired values. Correlation between 2 variables was assessed by using nonparametric Spearman correlation.
RESULTS

Circulating monocytes in patients with CGD display an inflammatory profile
We first investigated the circulating monocytes from patients with CGD followed at the Necker-Enfants Malades Hospital. Each patient's median age was 8 years (range, 1-22 years). No patients presented with active bacterial or fungal infection at the time of the study. Eight patients presented with inflammatory manifestations (colitis, n 5 7; granulomatous cystitis, n 5 1). Characteristics of the patients are detailed in Table I . Absolute counts of circulating monocytes were higher in patients with CGD versus HCs (median, 750/mL vs 400 mL, respectively; P 5 .006). The analysis of monocyte subsets, which were defined as CD14
1 CD16 2 classical, CD14 18 .5 6 9.7/mL and 13.6 6 6.5/mL for patients with CGD versus 6.7 6 3.8/mL and 4.4 6 2.4/mL, respectively, for HCs; P < .0001 and P 5 .0001; Fig 1, A and B) . This is reminiscent of other clinical inflammatory diseases in human subjects. 12, 13 Moreover, intracytoplasmic staining for the proinflammatory cytokines IL-1b, IL-6, IL-10 and TNF-a revealed increased content of IL-1b and TNF-a, as evaluated by using the geometric mean fluorescence intensity of the specific staining versus the isotype control, in monocytes of patients with CGD versus HCs. This increase was observed in all monocyte subsets (Fig 1, C-E) . 1 T cells after stimulation with phosphomolybdic acid (PMA) and calcium ionomycin (Fig 2, A) . The frequency of IL-17A-secreting CD4
1 T cells was significantly higher in patients with CGD (n 5 10) versus HCs (n 5 8; mean percentage of IL-17 1 CD4 1 T cells of 3.6 for patients with CGD vs 1.1% for HCs, P 5 .003). We did not observe an increase in the proportion of CD4 1 T cells producing concomitantly IFNg 1 and IL-17 1 in patients with CGD compared with that seen in HCs (data not shown). Interestingly, the increased frequency of IL-17A-secreting CD4
1 T cells was correlated with the increased age of patients (Spearman r 5 0.73, P 5 .02). However, we did not find any association between the frequency of IL-17A-secreting CD4
1 T cells and the existence of inflammatory manifestations or a history of fungal infection. In parallel, we also noted an increased proportion of TNF-a-secreting
CD4
1 T-cells after PMA/ionomycin stimulation in patients with CGD versus HCs (mean percentage, TNF-a 1 CD4 1 T cells of 50% for patients with CGD vs 23% for HCs; P 5 .001). We did not observe any difference in the proportion of IFN-g-and IL-4-secreting CD4
1 T cells. These data were confirmed by means of cytokine analysis of supernatant collected after 48 hours of polyclonal stimulation (anti-CD3/ CD28) because we noted a higher secretion of IL-17A (mean level, 769 6 260 pg/mL vs 314 6 72 pg/mL; P 5 .001), TNF-a (mean level, 4132 6 440 pg/mL vs 3511 6 195 pg/ mL; P 5 .005), and IL-6 (mean level, 2298 6 410 pg/mL vs 1052 6 410 pg/mL; P 5 .005) by CD4
1 T cells from patients with CGD (n 5 10) than CD4 1 T cells from HCs (n 5 6; Fig 2,  B) . It is noteworthy that CD4 1 T cells from patients with CGD secreted less IL-10 than CD4
1 T cells from HCs after stimulation (mean level, 2290 6 909 pg/mL vs 696 6 198 pg/mL; P 5 .004), leading to a higher IL-6/IL-10 proinflammatory ratio (Fig 2, B) .
Altogether, these data confirm the skewing of the T-helper profile toward T H 17 in patients with CGD. PMA/ionomycin stimulation in patients with CGD (n 5 10) and HCs (n 5 8) were stimulated with anti-CD3/CD28 for 48 hours. Supernatants were then collected for cytokine analysis by using a cytometric bead assay (MACSPlex). B, Purified total CD4 1 T cells obtained from patients with CGD (n 5 10) and HCs (n 5 6) were stimulated with anti-CD3/CD28 for 48 hours. Supernatants were then collected for cytokine analysis by using a cytometric bead assay (MACSPlex). *P < .05, **P < .01, and ***P < .001, Mann-Whitney U test. Extremities of the whiskers boxes represent minimum and maximum values. The bottom and top of the box represent the first and third quartiles, respectively. The horizontal bar in the box represents the median value.
Increased circulating IL-17A neutrophil numbers in patients with CGD
We next decided to evaluate the circulating neutrophil compartment from patients with CGD. Because human peripheral blood neutrophils are able to produce IL-17A after stimulation with IL-6 and IL-23 in a retinoic acid-related orphan receptor g (RORgt)-dependent manner, we investigated the presence of IL-17A-secreting neutrophils in patients with CGD using intracytoplasmic staining.
14 As shown in Fig 3, A, patients with CGD display a higher proportion and absolute number of IL-17A-secreting neutrophils in blood compared with HCs (mean, 0.4% 6 0.3% vs 0.08% 6 0.06% and 18 6 11/mL vs 3 6 2/mL, respectively; P 5 .002). Of note, the increased frequency of IL-17A-secreting neutrophils also correlated with the age of the patient (Spearman r 5 0.67, P 5 .039) but was not associated with the existence of inflammatory manifestations or history of fungal infection. Moreover, total neutrophils of patients with CGD tend to display a higher, although not significant, expression of the transcription factor RORgt than total neutrophils from HCs, as evidenced by intracytoplasmic staining (Fig 3, B) .
Effect of rapamycin on the inflammatory status of monocyte-derived macrophages from patients with CGD
Previous studies have shown that macrophages from patients with CGD present with a defect in autophagy. This defect in autophagy is associated with inflammasome activation and increased IL-1b release. 7 de Luca and et al 7 have also shown that IL-1 blockade with the receptor antagonist anakinra, in addition to inflammasome inhibition, restored autophagy in mice with CGD in vivo. Because autophagy and the inflammasome are mutually regulated, we wondered whether direct activation of autophagy could also inhibit inflammation activation in NADPH oxidase defective mononuclear phagocytes. Thus we decided to evaluate the inflammatory profile of mononuclear phagocytes from patients with CGD and the effect of rapamycin, a potent autophagy inducer, on this profile. 10 For this purpose, we performed macrophage differentiation of CD14 1 enriched monocytes from patients with CGD and HCs in serum free medium (X-VIVO 20; Lonza, Basel, Switzerland) supplemented with 100 ng/mL GM-CSF, a condition known to drive monocyte differentiation toward M1 macrophages. 15, 16 This differentiation was performed in the presence of dimethyl sulfoxide (DMSO) or 10 nmol/L rapamycin.
Supernatants collected at day 16 after monocyte differentiation toward M1 macrophages from patients with CGD and HCs were then analyzed for cytokine production. During their differentiation toward monocyte-derived macrophages (MDMs), monocytes from patients with CGD produced higher levels of IL-1b (34 6 19 pg/mL vs 14 6 5 pg/mL, P 5 .001), IL-6 (305 6 175 pg/mL vs 4 6 3 pg/mL, P 5 .0002), and TNF-a (1442 6 307 pg/mL vs 560 6 148 pg/mL, P 5 .0002) than monocytes from HCs (Fig 4, A, and see Fig E2, A, in this article's Online Repository at www. jacionline.org). These results are in agreement with previous studies and confirmed a preactivation state of macrophages from patients with CGD compared with those from HCs. To further characterize the inflammatory profile of macrophages from patients with CGD, we evaluated their cytokine secretion after 24 hours of LPS stimulation. LPS-stimulated MDMs from patients with CGD produced higher levels of IL-1b than LPS-stimulated MDMs from HCs (66 6 30 pg/mL vs 32 6 4 pg/mL, P 5 .001). Moreover, LPS-stimulated MDMs from patients with CGD secreted less IL-10 than MDMs from HCs (3296 6 491 pg/mL vs 2242 6 809 pg/mL, P 5 .03), leading to a higher IL-6/IL-10 proinflammatory ratio. We did not observe any difference in IL-6, IL-12 p70, IL-23, and TNF-a secretion after LPS stimulation between patients with CGD and HCs (Fig 4, B, and see Fig E2, B) .
Addition of 10 nmol/L rapamycin during CD14 1 monocyte differentiation toward macrophages did not seem to alter macrophage phenotype, as evaluated by the expression of CD11b, CD68, HLA-DR, and CD86, irrespective of whether monocytes originated from patients with CGD or HCs (see Fig E2, E) . As expected, addition of rapamycin in the culture medium decreased the level of phosphorylation on serine 235 and 236 of the S6 ribosomal protein (see Fig E2, C) 
org).
To investigate whether rapamycin could counterbalance the preactivation state of macrophages from patients with CGD, we analyzed cytokine secretion in supernatants collected at day 16 after monocyte differentiation toward macrophages from patients with CGD and HCs. If addition of rapamycin did not change the level of IL-1b and IL-6 secretion by MDMs from patients with CGD, it significantly reduced their TNF-a secretion (556 6 225 pg/mL for treated vs 1442 6 307 pg/mL for untreated MDMs, P 5 .0002; Fig 4, A) . These results were confirmed by means of intracytoplasmic staining for IL-1b, IL-6, and TNF-a (see Fig E2, C and D) .
To determine the effect of rapamycin on macrophage activation, we stimulated treated and untreated (DMSO) MDMs from patients with CGD and HCs with 100 ng/mL LPS for 24 hours and collected supernatant for cytokine analysis. After LPS stimulation, MDMs from patients with CGD treated with rapamycin produced lower levels of IL-1b (36 6 22 pg/mL vs 66 6 30 pg/mL, P 5 .006), IL-6 (1451 6 818 pg/mL vs 2899 6 988 pg/mL, P 5 .002), IL-23 (1260 6 399 pg/mL vs 92 6 80 pg/mL, P 5 .001), and TNF-a (1053 6 763 pg/mL vs 2881 6 1135 pg/mL, P 5 .002; Fig 4, B, and see Fig E2, B) . If IL-10 production by LPS-stimulated MDMs was also significantly reduced (P 5 .002) by rapamycin treatment, the IL-6/IL-10 proinflammatory ratio was significantly decreased by the addition of the mTOR inhibitor (data not shown, P 5 .002). The same changes in cytokine production were observed for LPS-stimulated MDMs from HCs.
To assess the effect of rapamycin on inflammasome activation, we stimulated MDMs from patients with CGD with LPS and ATP and evaluated caspase-1 activity using a fluorescent inhibitor of active caspase-1 (Fig 4, C and D) . As anticipated, rapamycin decreased inflammasome activation in MDMs from patients with CGD.
Altogether, these data show that rapamycin is not only able to inhibit IL-1b secretion by MDMs through inflammasome inhibition but significantly reduces the inflammatory profile of NADPH-deficient cells.
Counterbalance of the T H 17 profile of CD4
1 T cells from patients with CGD by rapamycin
RORgt serves as the master regulator for T H 17 cells, and enhanced expression of RORgt in naive CD4
1 T cells induces genes essential for T H 17 differentiation. 17, 18 Studies have shown that suppression of the phosphoinositide 3-kinase-Akt-mTORC1 axis, which accelerates nuclear translocation of RORgt to the nucleus, impairs T H 17 differentiation in vitro and in vivo in a S6K1/2-dependent fashion. 19, 20 We wondered whether rapamycin could reverse the T H 17 cytokine secretion profile observed in CD4 1 T cells from patients with CGD independently of its action on the production of pro-T H 17 cytokines by phagocytic cells. Purified total CD4 1 T cells obtained from patients with CGD (n 5 6) were stimulated with anti-CD3/ CD28 for 48 hours with or without (DMSO) 10 nmol/L rapamycin. Supernatants were then collected for cytokine analysis by using a cytometric bead assay (MACSPlex; Miltenyi Biotech, Bergisch Gladbach, Germany). CD4 1 T cells from patients with CGD treated with rapamycin produced lower levels of IL-6 (810 6 290 pg/mL for rapamycin-treated cells vs 1475 6 423 pg/mL for untreated cells, P 5 .03), IL-17A (292 6 121 pg/mL vs 896 6 241 pg/mL, P 5 .03), and TNF-a (1766 6 364 pg/mL vs 4696 6 421 pg/mL, P 5 .03), with a reduction in the IL-6/IL-10 proinflammatory ratio (Fig 4, E) . . Supernatants were then collected for cytokine analysis by using a cytometric bead assay (MACSPlex). F and G, CD14 1 monocytes from patients with CGD (n 5 8) were treated for 24 hours with 10 nmol/L rapamycin and increasing dose of anakinra (ie, 0, 40, and 400 ng/mL) before 4 hours of stimulation with LPS. Monocytes were then analyzed for IL-1b (Fig 4, F) and TNF-a secretion (Fig 4, G) . *P < .05, **P < .01, and ***P < .001, Mann-Whitney U test or Wilcoxon paired t test.
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Combination therapy of rapamycin and anakinra
We then wondered whether anakinra, a competitive inhibitor of the binding of IL-1 to its receptor, could enhance the antiinflammatory action of rapamycin. Whole blood from patients with CGD (n 5 8) was incubated for 24 hours with rapamycin or DMSO and increasing dose of anakinra (ie, 0, 40, and 400 ng/mL) before stimulation with LPS. 21 Secretion of IL-1b and TNF-a by monocytes from patients with CGD was evaluated by means of intracytoplasmic staining (Fig 4, F and G) 18 .6% for samples treated with rapamycin and low-dose anakinra; P 5 .015). We did not observe a benefit to the increase in anakinra dose. Of note, the combination of low-dose anakinra plus rapamycin reduced more efficiently IL-1b secretion than low-dose anakinra alone (mean percentage of IL-1b 1 monocytes, 27.3% for samples treated with low-dose anakinra vs 18.6% for samples treated with rapamycin and low-dose anakinra; P 5 .015). Anakinra had no effect on TNF-a 1 secretion by monocytes after LPS stimulation. Its combination with rapamycin did not enhance the inhibitory effect of rapamycin on TNF-a 1 secretion.
DISCUSSION
The progress in management of CGD has underscored the burden of inflammatory/granulomatous manifestations in patients with CGD. Indeed, patients with CGD have granulomatous disorders involving diverse organs with a high prevalence, up to 69% depending on the reported series. 2 We report herein one of the largest series analyzing the inflammatory phenotype of patients presenting with CGD. Independent of any active chronic infection, patients with CGD present a biological inflammatory state involving all immune cell subsets. It is noteworthy that even in patients free of evident inflammatory manifestations, we observed a consistent inflammatory phenotype characterized by (1) increased nonclassical and intermediate monocytes, (2) a proinflammatory state of mononuclear phagocytes with increased IL-1b and TNF-a content, (3) a T H 17 bias of CD4 1 T cells, and (4) an increase in IL-17A-secreting neutrophils.
The increase in nonclassical and intermediate monocyte counts is a common feature observed in patients with diverse inflammatory conditions. 12, 13 Our data on monocytes and MDMs are in line with those of previous reports underlying the important role of IL-1b and TNF-a in CGD pathophysiology of inflammatory manifestations. 4, 5, 7, 22 We report a T H 17 bias of CD4 1 T cells in patients with CGD, a feature that has already been described by others. 23 This bias could be related to production of the key T H 17-polarizing cytokines IL1b, IL-6, and IL-23 and TGF-b by mononuclear phagocytes, as reported in our study and by others. 24 Even if activation of the IL-17/ IL-23 axis has been implicated in the pathogenesis of inflammatory conditions, such as multiple sclerosis, inflammatory bowel disease, or Behçet disease, the contribution of a T H 17 imbalance in the genesis of inflammatory lesions from patients with CGD still remains unclear despite some data obtained in NADPHdeficient mice. [25] [26] [27] [28] Interestingly, we identified the presence of a subset of IL-17A-secreting neutrophils in patients with CGD. This finding is reminiscent of the neutrophil population described by Taylor et al 14 that produces IL-17A in an RORgt-dependent manner and uses it in an autocrine manner to enhance reactive oxygen species production and antifungal activity.
It is noteworthy that the increase in nonclassical and intermediate monocyte counts and the higher frequency of IL-17A-producing CD4
1 T cells and neutrophils reported did not seem to be associated with the presence of inflammatory manifestations. The apparent lack of association between inflammatory conditions and these biological features could result from the anti-inflammatory therapy received by some patients and/or the existence of subclinical inflammatory manifestations. Nevertheless, the significant correlation noted between IL-17A-producing CD4
1 T cells and neutrophils and the age of the patient underline the importance of time in the occurrence of inflammatory complications in patients with this disease. 2 Through the last decade, several groups have studied the mechanisms responsible for the inflammatory status observed in patients with CGD, showing that mononuclear phagocytes from these patients present with a defect in autophagy. 29 This defect in autophagy results in activation of the inflammasome and increased IL-1b release. 4, 7 Because some experimental data have shown the potential benefit of IL-1 blockade with the receptor antagonist anakinra in patients with CGD, attempts have been made to treat patients with CGD presenting with inflammatory manifestations with the IL-1b receptor antagonist (anakinra), with mixed results. 6, 7 Targeting the same pathway, we decided to evaluate the benefit of rapamycin treatment on CGD-related inflammation. Because rapamycin has been shown to act as an autophagy inducer through mTORC1 inhibition, 10 we reasoned that restoring the autophagy defect in patients with CGD might contribute to reversion of the biological inflammation observed in patients with CGD. We report that rapamycin is indeed able to significantly reduce basal TNF-a production and secretion from MDMs. Through autophagy induction and caspase-1 inhibition, rapamycin inhibits efficiently IL-1b secretion by LPSprimed MDMs. This is in accordance with some recent data showing that blocking autophagy potentiated inflammasome activity, whereas stimulating autophagy limited it. 30 Moreover, rapamycin treatment of LPS-primed MDMs significantly reduced their secretion of TNF-a and other key T H 17-polarizing cytokines (ie, IL-6 and IL-23). In accordance with data showing that suppression of the phosphoinositide 3-kinase-Akt-mTORC1 axis impairs T H 17 differentiation in vitro and in vivo, we show that rapamycin corrects the T H 17 cytokine secretion profile observed in CD4
1 T cells from patients with CGD independently of its action on the production of pro-T H 17 cytokines by mononuclear phagocytes. 19, 20 Finally, we show that inhibition of IL-1 receptor with the antagonist anakinra, even at low doses, enhances the inhibitory effect of rapamycin on IL-1b secretion by phagocytes in vitro, suggesting that the combinatory therapy of rapamycin and anakinra could be beneficial for treatment of patients with CGD with inflammatory complication that have no or only a partial response to anakinra.
Taken together, all these data suggest that rapamycin could be a useful therapy for managing inflammatory manifestations in patients with CGD. Until recently, treatment of inflammatory/ granulomatous manifestations has been mainly based on corticosteroids, but steady progress in the understanding of CGD pathophysiology have prompted the use of alternative therapies, such as anti-TNF-a mAbs, thalidomide, or anakinra. 4, 6, 7, 31, 32 Compared with these therapies, rapamycin has the advantage of (1) inhibiting the constitutive inflammasome activation of phagocytes from patients with CGD through autophagy induction, (2) having additional immunomodulatory properties independent of caspase-1 inhibition (ie, inhibition of secretion of TNF-a, IL-6, and IL-23 by mononuclear phagocytes and inhibition of TNF-a, IL-6, and IL-17A by T cells), and (3) being ironically an antifungal agent despite its known immunosuppressive properties. 8 Finally, rapamycin could help correct the decrease in the functional activity of hematopoietic stem cells observed in patients with CGD because data show that the suppression of the mTOR pathway allows for the ex vivo maintenance of human and mouse long-term HSCs. [33] [34] [35] This could be of great interest in view of an HSC-based gene therapy protocol for CGD.
However, the true place of rapamycin in the management of CGD-related inflammatory complications remains to be assessed through controlled clinical trials. Such studies will help determine the real efficacy of rapamycin compared with standard therapy (ie, corticosteroid) and/or its potential ability to reduce the corticosteroid burden in patients with CGD with inflammatory conditions and corticosteroid dependence. Clinical implications: This study suggests that patients with CGD with steroid-refractory/dependent inflammatory manifestation could benefit from a rapamycin treatment.
METHODS
Purification of total CD4
1 T lymphocytes 
Intracytoplasmic staining
Intracytoplasmic staining of CD4 1 T cells was performed on purified (Fig E1, A) and TNF-a (Fig E1, C) in unstimulated CD4 1 T cells of patients with CGD and
HCs. B and D, Intracellular content of IL-17A (Fig E1, B) and TNF-a (Fig E1, D) in unstimulated CD4 1 T cells of patients with CGD (n 5 14) and HCs (n 5 10) evaluated based on the ratio between the geometric mean fluorescence intensity (GMFI) of the specific staining versus isotype control. *P < .05 and **P < .01, Mann-Whitney U test). Extremities of the whiskers boxes represent minimum and maximum values. The bottom and top of the box represent the first and third quartiles, respectively. The horizontal bar in the box represents the median value.
FIG E2. Effect of rapamycin on MDMs from patients with CGD. A, CD14
1 monocytes from patients with CGD (n 5 15, 18 samples) and HCs (n 5 7, 7 samples) were differentiated into macrophages with or without (DMSO) rapamycin. Supernatants were collected at day 16 after differentiation, and cytokines were analyzed by using a cytometric bead assay (MACSPlex) or ELISA. B, MDMs from patients with CGD (n 5 12) and HCs (n 5 5) were stimulated for 24 hours with 100 ng/mL LPS in the presence or not (DMSO) of 10 nmol/L rapamycin. Supernatants were collected for cytokine analysis by using a cytometric bead assay (MACSPlex) or ELISA. C, MDMs from patients with CGD treated or not with 10 nmol/L rapamycin were analyzed for S235-236 phospho-S6 ribosomal protein IL-1b, IL-6, and TNF-a expression by means of intracytoplasmic staining. D, Geometric mean fluorescence intensity (GMFI) ratio between IL-1b or TNF-a and the isotype control in MDMs from patients with CGD (n 5 5) versus HCs (n 5 4) at day 16 after differentiation. E, Expression of CD11b, CD68, HLA-DR, and CD86 by MDMs from patients with CGD after differentiation in the presence or absence (DMSO) of 10 nmol/L rapamycin. **P < .01, Mann-Whitney U test or Wilcoxon paired t test. Extremities of the whiskers boxes represent minimum and maximum values. The bottom and top of the box represent the first and third quartiles, respectively. The horizontal bar in the box represents the median value. 
